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The prognostic value of systemic inﬂammation in patients
undergoing surgery for colon cancer: comparison of composite
ratios and cumulative scores
Ross D Dolan1, Stephen T McSorley 1, James H Park1, David G Watt1, Campbell S Roxburgh1, Paul G Horgan1 and Donald C McMillan1
INTRODUCTION: The systemic inﬂammatory response has been proven to have a prognostic value. There are two methods of
assessing the systemic inﬂammatory response composite ratios (R) and cumulative scores (S). The aim of this study was to compare
the prognostic value of ratios and scores in patients undergoing surgery for colon cancer.
METHODS: Patients were identiﬁed prospectively in a single surgical unit. Preoperative neutrophil (N), lymphocyte (L), monocyte
(M) and platelet (P) counts, CRP (C) and albumin (A) levels were recorded. The relationship between composite ratios
neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), lymphocyte–monocyte ratio (LMR), C-reactive protein albumin
ratio (CAR) and the cumulative scores neutrophil– lymphocyte score (NLS), platelet–lymphocyte score (PLS), lymphocyte–monocyte
score (LMS), neutrophil– platelet score (NPS), modiﬁed Glasgow prognostic score (mGPS) and clinicopathological characteristics,
cancer-speciﬁc survival (CSS) and overall survival (OS), were examined.
RESULTS: A total of 801 patients were examined. When adjusted for tumour node metastasis (TNM) stage, NLR >5 (p < 0.001), NLS
(p < 0.01), PLS (p < 0.001), LMR <2.4 (p < 0.001), LMS (p < 0.001), NPS (p < 0.001), CAR >0.22 (p < 0.001) and mGPS (p < 0.001) were
signiﬁcantly associated with CSS. In patients undergoing elective surgery (n= 689), the majority of the composite ratios/scores
correlated with age (p < 0.01), BMI (p < 0.01), T stage (p < 0.01), venous invasion (p < 0.01) and peritoneal involvement (p < 0.01).
When NPS (myeloid) and mGPS (liver) were directly compared, their relationship with CSS and OS was similar.
CONCLUSIONS: Both composite ratios and cumulative scores had prognostic value, independent of TNM stage, in patients with
colon cancer. However, cumulative scores, based on normal reference ranges, are simpler and more consistent for clinical use.
British Journal of Cancer (2018) 119:40–51; https://doi.org/10.1038/s41416-018-0095-9
INTRODUCTION
Colorectal cancer is the fourth most common cancer in the United
Kingdom and the second most common cause of cancer death.1
Despite death rates from colorectal cancer falling by approxi-
mately 14% over the last decade, approximately 40% of those
diagnosed will die from their colorectal cancer. Surgery remains
the primary modality of cure in these patients and therefore there
is a continuing interest in factors that will effectively identify
patients at high risk of dying from their disease following
potentially curative surgery.
Over the last decade or so it has become clear that markers of
the systemic inﬂammatory response are clinically useful to identify
patients at high risk of tumour progression in a variety of common
solid tumours, in particular lung and gastrointestinal cancer.2,3
These markers of the systemic inﬂammatory response are usually
based around composite ratios or cumulative scores of different
circulating white blood cells or acute phase proteins representing
the systemic responses of two different organs, lymphoid/myeloid
tissue and liver, respectively (Table 1). There have been two main
approaches to the formation of these prognostic scores. One
approach is to take the ratio of different white blood cells and
then apply a prognostic threshold to the ratio such that outcome
is effectively stratiﬁed. The most repeatedly validated example of
this approach is the neutrophil–lymphocyte ratio (NLR) based on
the ratio of circulating neutrophil and lymphocyte counts
(Table 1).2,3 Other validated examples are the platelet–lymphocyte
ratio (PLR) based on the ratio of circulating platelet and
lymphocyte counts (Table 1) and the lymphocyte–monocyte score
(LMR) based on the ratio of circulating lymphocyte and monocyte
counts (Table 1).2,3 Also, recently a similar approach has been
applied to the acute phase proteins, C-reactive protein and
albumin, and C-reactive protein albumin ratio (CAR) has been
recently validated (Table 1).2,3 Although it is clear that the above
ratios have prognostic value, a disadvantage of the ratio approach
is that, depending on the threshold used, an abnormal ratio may
be deﬁned with one or both markers having a normal value.
A simpler approach is the cumulative prognostic score, where
markers of the systemic inﬂammatory response are deﬁned as
normal or as abnormal based on their laboratory reference ranges
such that two markers with normal values score lowest and have
the best outcomes and two markers with abnormal values score
highest and have the poorest outcomes. The most widely
validated example of this approach is the Glasgow prognostic
score (mGPS) based on the acute phase proteins, C-reactive
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protein and albumin (Table 1).2,3 Also, recently the
neutrophil–platelet score (NPS) using neutrophils and platelets
has been reported.4 Clearly, the cumulative score approach can
also be applied to the ratios described above (Table 1), such as
NLR (termed neutrophil–lymphocyte score (NLS)), PLR (termed
platelet–lymphocyte score (PLS)) and LMR (termed
lymphocyte–monocyte score (LMS)).
Therefore, the aim of the present study was to compare the
prognostic value of systemic inﬂammatory markers, in particular
that of composite ratios and cumulative scores, in patients
undergoing surgery for colon cancer.
PATIENTS AND METHODS
Patients were identiﬁed from a prospectively collected and
maintained database of colon cancer resections undertaken in a
single surgical unit at the Glasgow Royal Inﬁrmary. Consecutive
patients who met the following criteria were included: ﬁrst, those
who had preoperative measurement of serum CRP, albumin and
Table 1. Systemic inﬂammation-based prognostic ratios and scores
Ratio/score Ratio/score
NLR
Neutrophil count: lymphocyte count ≤3
Neutrophil count: lymphocyte count 3–5
Neutrophil count: lymphocyte count >5
NLS
Neutrophil count ≤7.5 × 109/l and lymphocyte count ≥1.5 × 109/l 0
Neutrophil count >7.5 × 109/l and lymphocyte count ≥1.5 × 109/l 1
Neutrophil count ≤7.5 × 109/l and lymphocyte count <1.5 × 109/l 1
Neutrophil count >7.5 × 109/l and lymphocyte count <1.5 × 109/l 2
PLR
Platelet count: lymphocyte count ≤150
Platelet count: lymphocyte count >150
PLS
Platelet count ≤400 × 109/l and lymphocyte count ≥1.5 × 109/l 0
Platelet count >400 × 109/l and lymphocyte count ≥1.5 × 109/l 1
Platelet count ≤400 × 109/l and lymphocyte count <1.5 × 109/l 1
Platelet count >400 × 109/l and lymphocyte count <1.5 × 109/l 2
LMR
Lymphocyte count: monocyte count ≥2.40
Lymphocyte count: monocyte count <2.40
LMS
Lymphocyte count ≥1.5 × 109/l and monocyte count ≤0.80 × 109/l 0
Lymphocyte count ≥1.5 × 109/l and monocyte count ≤0.80 × 109/l 1
Lymphocyte count <1.5 × 109/l and monocyte count >0.80 × 109/l 1
Lymphocyte count <1.5 × 109/l and monocyte count >0.80 × 109/l 2
NPS
Neutrophil count ≤7.5 × 109/l and platelet count <400 × 109/l 0
Neutrophil count >7.5 × 109/l and platelet count <400 × 109/l 1
Neutrophil count ≤7.5 × 109/l and platelet count >400 × 109/l 1
Neutrophil count >7.5 × 109/l and platelet count >400 × 109/l 2
CAR
C-reactive protein: albumin ≤0.22
C-reactive protein: albumin >0.22
mGPS
C-reactive protein ≤10mg/l and albumin ≥35 g/l 0
C-reactive protein >10mg/l and albumin ≥35 g/l l 1
C-reactive protein >10mg/l and albumin <35 g/l l 2
NLR neutrophil–lymphocyte ratio, NLS neutrophil–lymphocyte score, CAR C-
reactive protein albumin ratio, mGPS modiﬁed Glasgow prognostic score,
NPS neutrophil–platelet score, LMS lymphocyte–monocyte score, LMR
lymphocyte–monocyte ratio, PLR platelet–lymphocyte ratio, PLS
platelet–lymphocyte score
Table 2a. The clinicopathological characteristics of patients
undergoing surgery for colon cancer (n= 801)
Variables n= 801 (%)
Age (years)
<65 248 (31)
65–74 270 (34)
>75 283 (35)
Sex
Female 371 (46)
Male 430 (54)
BMIa
Underweight 72 (12)
Normal 190 (31)
Overweight 192 (32)
Obese 153 (25)
ASA gradeb
1 97 (17)
2 243 (42)
3 208 (36)
4 29 (5)
Presentation
Elective 689 (86)
Emergency 112 (14)
Type of surgery
Open 679 (85)
Laparoscopic 122 (15)
Neoadjuvant therapyc
No 782 (99)
Yes 8 (1)
Adjuvant therapyd
No 574 (75)
Yes 194 (25)
T stage
1 52 (6)
2 76 (10)
3 418 (52)
4 255 (32)
N stage
0 507 (63)
1 207 (26)
2 87 (11)
TNM stage
1 116 (14)
2 391 (49)
3 294 (37)
Differentiatione
Mod/well 709 (89)
Poor 86 (11)
Venous invasionf
No 383 (48)
Yes 416 (52)
Margin involvementf
No 757 (95)
Yes 42 (5)
Peritoneal involvementf
No 578 (72)
Yes 221 (28)
Tumour perforationf
No 772 (97)
Yes 27 (3)
an= 607. bn = 575. cn= 790. dn = 778. en= 795. fn= 799. BMI body mass
index, ASA American Society of Anaesthesiologists, TNM tumour node
metastasis
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differential blood cell counts within 30 days before surgery;
second, those who, on the basis of preoperative abdominal
computed tomography and laparotomy ﬁndings, were considered
to have undergone potentially curative resection for colonic
cancer between January 1997 and June 2014. Patients with
inﬂammatory bowel disease-related cancer, who underwent
resection with palliative intent or local resection only, or had not
had preoperative measurement of CRP or albumin, were
excluded.5 Tumours were staged using the ﬁfth edition of the
tumour node metastasis (TNM) classiﬁcation, with additional data
taken from pathological reports issued after resection.6 After
surgery, all patients were discussed at a multidisciplinary meeting
involving surgeons, oncologists, radiologists and pathologists with
special interest in colorectal cancer; patients with stage III or high-
risk stage II disease and no signiﬁcant comorbidities precluding
chemotherapy use were offered primarily 5-ﬂuorouracil-based
adjuvant chemotherapy on the basis of current guidelines at the
time.
Preoperative serum CRP, albumin and differential blood cell
counts were recorded prospectively. NLR, PLR, LMR and CAR were
all calculated by directly dividing the former by the latter (Table 1).
The NLS, PLS, LMS, NPS and mGPS were all constructed using
normal reference ranges (Table 1).
Patients were routinely followed up for 5 years after surgery.
Date and cause of death were crosschecked with the cancer
registration system and the Registrar General (Scotland). Death
records were complete until 30 June 2017, which acted as the
censor date. Cancer-speciﬁc survival (CSS) was measured from the
date of surgery until the date of death from recurrent or
metastatic colonic cancer. Overall survival (OS) was measured
until the date of death from any cause. The West of Scotland
Research Ethics Committee approved the study.
Statistics
The cut-off values for individual ratios were examined using
receiver operating characteristic (ROC) curve analyses. The
threshold values of such characteristics were based on the most
prominent point on the ROC curve for 'sensitivity' and '1-
speciﬁcity', respectively. The optimal threshold values were
deﬁned using the Youden index (maximum (sensitivity+ speciﬁ-
city− 1)) and these were compared with published validated
values to determine the value used in the subsequent analysis.7,8
The area under the ROC curve also was calculated. The relation-
ship between NLR, PLR, LMR, CAR, NLS, PLS, LMS and mGPS and
both CSS and OS was assessed using Cox proportional hazards
regression to calculate hazard ratios (HRs) and 95% conﬁdence
intervals (95% CIs). The relationship between NLR, PLR, LMR, CAR,
NLS, PLS, LMS and mGPS and patient clinicopathological
characteristics was assessed using Pearson's χ2 tests. In order to
adjust for multiple comparisons during the correlation of
composite ratios and cumulative scores and clinicopathological
characteristics a p value of <0.01 was considered signiﬁcant. All
analyses were performed using SPSS version 22.0 (IBM Corp,
Armonk, NY, USA).
RESULTS
From the prospectively maintained database, 801 patients under-
going potentially curative resection for colon cancer were
examined (Table 2a). The majority of patients were over 65 years
of age (69%), were male (54%), were overweight or obese (57%)
and were American Society of Anaesthesiologists' grade 2 or
greater (83%). The majority of patients presented electively (86%),
had an open resection (85%) and did not receive adjuvant therapy
(75%). The majority of patients had either TNM stage II or III
disease (86%) with moderate/well- differentiated tumours (n=
703, 89%) and venous invasion (52%). The majority of patients had
no margin involvement (95%), peritoneal involvement (72%) or
tumour perforation (97%) at the time of resection. On follow-up
there were 237 (28%) cancer-related deaths and 437 (52%) deaths
overall.
The relationship between the composite ratios and cumulative
scores and the clinicopathological characteristics of patients
undergoing elective surgery for colon cancer is shown in Table 2b
(n= 689). There was statistically signiﬁcant correlation between
the majority of the composite ratios and cumulative scores and
age (p < 0.01), BMI (p < 0.01), T stage (p < 0.01), venous invasion (p
< 0.01) and peritoneal involvement (p < 0.01).
The relationship between composite ratios and cumulative
scores and their component values in patients undergoing surgery
for colon cancer is shown in Table 2c (n= 801). The majority were
not assigned as systemically inﬂamed prior to surgery according
to either ratios or scores (NLR >5—19%, NLS >0—47%, PLR >150
—65%, PLS >0—48%, NPS >0—28%, CAR >0.22—49%, mGPS >0
—41%).
The median values for the components of the ratios and scores
are shown in Table 2c. An NLR 3–5 was associated with a median
neutrophil count of 5.5 × 109/l and a median lymphocyte count of
1.5 × 109/l, both within the normal reference range. In contrast, an
NLR >5 was associated with a median neutrophil count of 8.5 ×
Table 2b. The correlation between composite ratios and cumulative scores and clinicopathological characteristics of patients undergoing elective
surgery for colon cancer (n= 689)
Age Sex BMI ASA
grade
T stage N stage Differentiation Venous
invasion
Margin
involvement
Peritoneal
involvement
Tumour
perforation
Adjuvant
therapy
NLR 0.009 0.398 <0.001 0.156 0.069 0.287 0.018 0.002 0.219 0.195 <0.001 0.063
NLS 0.002 0.746 0.003 0.880 0.039 0.504 0.073 0.078 0.069 0.062 0.004 0.301
PLR <0.001 0.391 <0.001 0.294 0.001 0.395 0.087 0.214 0.095 0.002 0.803 0.758
PLS 0.008 0.827 <0.001 0.337 0.001 0.449 0.029 0.002 0.012 0.005 0.043 0.907
LMR <0.001 0.004 0.030 0.705 0.063 0.948 0.557 0.133 0.750 0.085 0.041 0.067
LMS <0.001 0.872 0.165 0.841 0.001 0.412 0.044 0.158 0.033 <0.001 0.184 0.097
NPS 0.649 0.990 0.016 0.753 0.004 0.017 0.005 0.013 0.015 0.277 0.375 0.341
CAR 0.008 0.618 0.027 0.009 <0.001 0.071 0.001 0.011 0.037 0.007 0.004 0.341
mGPS 0.180 0.913 <0.001 0.294 <0.001 0.616 <0.001 0.006 0.005 0.003 0.001 0.422
*p <0.01 is considered signiﬁcant. NLR neutrophil–lymphocyte ratio, NLS neutrophil–lymphocyte score, CAR C-reactive protein albumin ratio, mGPS modiﬁed
Glasgow prognostic score, NPS neutrophil–platelet score, LMS lymphocyte–monocyte score, LMR lymphocyte–monocyte ratio, PLR platelet–lymphocyte ratio,
PLS platelet–lymphocyte score
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Table 2c. The relationship between composite ratios and cumulative scores and their component values in patients undergoing surgery for colon
cancer (n= 801)
n (%) Median (range) Median (range)
Neutrophil Lymphocyte
NLR
≤3 388 (48.4) 4.2 (0.4–9.0) 2.0 (0.7–14.1)
3–5 260 (32.5) 5.5 (2.1–17.5) 1.5 (0.5–4.7)
>5 153 (19.1) 8.5 (2.2–21.3) 1.1 (0.3–2.5)
NLS
0 421 (52.6) 4.8 (1.7–7.5) 2.0 (1.5–14.1)
1 325 (40.6) 5.1 (0.4–20.6) 1.3 (0.3–4.70)
2 55 (6.9) 9.9 (7.6–21.3) 1.1 (0.5–1.4)
Platelet Lymphocyte
PLRa
≤150 237 (34.8) 248 (93–653)
2.1 (1.0–14.1)
>150
445 (65.2) 325 (119–814) 1.40
(0.30–4.70)
PLSa
0 351 (51.5) 282 (94–396) 2.0 (1.5–14.1)
1 283 (41.5) 292 (93–814) 1.3 (0.3–11.0)
2 48 (7.0) 478 (406–698) 1.1 (0.6–1.4)
Lymphocyte Monocyte
LMRb
≥2.4 252 (61.0) 1.9 (0.6–14.1)
0.6 (0.1–1.3)
<2.4
161 (39.0) 1.3 (0.3–3.0) 0.8 (0.3–2.0)
LMSb
0 214 (51.8) 2.0 (1.5–14.1) 0.6 (0.1–0.8)
1 169 (40.9) 1.3 (0.3–4.6) 0.7 (0.1–2.0)
2 30 (7.3) 1.2 (0.6–1.4) 1.0 (0.9–1.9)
Neutrophil Platelet
NPSa
0 491 (72.0) 4.5 (0.4–7.50) 268 (93–400)
1 140 (20.5) 6.7 (2.3–18.8) 415 (96–811)
2 51 (7.5) 9.8 (7.6–20.60) 474 (406–814)
CRP Albumin
CAR
≤0.22 412 (51.4) 5 (0.1–9)
38 (21–49)
>0.22
389 (48.6) 22 (6–339) 35 (15–47)
mGPS
0 474 (59.2) 5 (0.1–10) 38 (21–49)
1 173 (21.6) 22 (11–220) 38 (35–47)
2 154 (19.2) 37 (11–339) 31 (15–34)
an= 682. bn= 413. NLR neutrophil–lymphocyte ratio, NLS neutrophil–lymphocyte score, CAR C-reactive protein albumin ratio, mGPS modiﬁed Glasgow
prognostic score, NPS neutrophil–platelet score, LMS lymphocyte–monocyte score, LMR lymphocyte–monocyte ratio, PLR platelet–lymphocyte ratio, PLS
platelet–lymphocyte score
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109/l and a median lymphocyte count of 1.1 × 109/l, both outside
the normal reference range. A PLR >150 was associated
with a median platelet count of 325 × 109/l and a median
lymphocyte count of 1.4 × 109/l, the platelet count being within
the normal reference range. An LMR <2.4 was associated with
a median lymphocyte count of 1.3 × 109/l and a median
monocyte count of 0.8 × 109/l, monocyte count being within
the normal reference range. A CAR >0.22 was associated with a
median CRP concentration of 24 mg/l and a median albumin
concentration of 36 g/l, with albumin being within the normal
reference range.
The relationship between validated ratios, scores and 5-year CSS
in patients undergoing surgery for colon cancer is shown in
Table 3 and Figs. 1–4. On ROC analysis using standard thresholds
and CSS as an end-point, the AUC for TNM stage was 0.649, NLR
was 0.577, NLS was 0.566, PLR was 0.538, PLS was 0.607, LMR was
0.613, LMS was 0.605, NPS was 0.580, CAR was 0.582 and mGPS
was 0.591. When adjusted for TNM stage, NLR >5 (p < 0.001), NLS 1
and 2 (both p ≤ 0.01), PLS 2 (p < 0.001), LMR <2.4 (p < 0.001), LMS 2
(p < 0.001), NPS 2 (p ≤ 0.001), CAR >0.22 (p < 0.001), mGPS 2 (p <
0.001) were signiﬁcantly associated with CSS.
On ROC analysis using standard thresholds and 5-year OS as an
end-point, the following AUC for TNM stage was 0.569, NLR was
0.594, NLS was 0.586, PLR was 0.555, PLS was 0.620, LMR was
0.590, LMS was 0.585, NPS was 0.576, CAR was 0.603 and mGPS
was 0.623. When adjusted for TNM stage, NLR >5 (p < 0.001), NLS 1
and 2 (both p ≤ 0.01), PLS 2 (p < 0.001), LMR <2.4 (p < 0.001), LMS 2
(p < 0.001), NPS 2 (p ≤ 0.01), CAR >0.22 (p < 0.001), mGPS 2 (p <
0.001) were all signiﬁcantly associated with overall survival (Table 3
and Figs. 1–4).
The complementary prognostic value of the cumulative scores
NPS and mGPS, markers of innate immune activation from two
different organs, were examined in the context of TNM staging
(Table 4). Within TNM stage II disease the 5-year CSS rate was 82%
and the 5-year CSS rate varied between 86 and 73% according to
the NPS and between 86 and 79% according to the mGPS. The 5-
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year OS rate was 57% and the 5-year OS rate varied between 61
and 47% according to the NPS and between 65 and 48%
according to the mGPS.
Within TNM stage III disease, the 5-year CSS rate was 65% and
the 5-year CSS rate varied between 67 and 60% according to the
NPS and between 69 and 59% according to the mGPS. The 5-year
OS rate was 47% and the 5-year OS varied between 51 and 37%
according to the NPS and between 53 and 38% according to the
mGPS (Table 4).
DISCUSSION
The results of the present study directly compare, for the ﬁrst
time, the prognostic value of composite ratios and cumulative
scores of the systemic inﬂammatory response. These ratios and
scores, whether composed of white cells from lymphoid/myeloid
tissue or from acute phase proteins from the liver, had
prognostic value, independent of TNM stage, in patients with
colon cancer. Moreover, systemic inﬂammation scores from
different organs had similar prognostic value. Taken together,
the systemic inﬂammatory response represents an important
prognostic domain to be monitored in patients with colon
cancer.
In the present study, it was of interest that the ratio thresholds
did not always differentiate normal from abnormal values of the
composite values. The discrepancy between the ratio threshold
and the abnormal single component is shown in Fig. 5a–e. In
Fig. 5a, using the line of best ﬁt, an NLR >5 was associated with a
median neutrophil count of approximately 7.5, at the top of the
normal reference range. In contrast, a NLR >3 was associated with
a neutrophil count of approximately 4.5, within in the normal
reference range. With reference to PLR >150, it was associated
with a platelet count of approximately 200, within the normal
range (Fig. 5b). With reference to LMR <2.4, it was associated with
a lymphocyte count of 1.5, at the bottom of the normal range
(Fig. 5c). Finally, with reference to CAR >0.22 was associated with a
CRP of 10 well above the normal range (Fig. 5d). Therefore, it is
clear that a number of ratios (e.g. NLR >3 and PLR >150) do not
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describe components with abnormal values. Moreover, the ratios,
compared with scores, consistently assigned a higher proportion
of patients to be systemically inﬂamed. Given that scores based on
abnormal value are simpler to construct and have similar and
overlapping prognostic value, independent of TNM stage,
compared with composite ratios (Table 3), the rationale for the
continued use of such ratios is problematic. Indeed, recent clinical
calculators for survival in patients with metastatic colorectal
cancer, based on data of more than 20,000 patients from
randomised controlled trials (ARCAD database), has incorporated
the white cell count, neutrophil count, platelet count and albumin
level as scores rather than derived ratios.9,10 Furthermore Dupré
and Malik11 have argued that the variability of reported prognostic
thresholds of NLR, PLR and LMR questions their reliability for
routine clinical practice.
Although it is presumed that composite ratios of lymphoid/
myeloid cells and acute phase proteins reﬂect similar aspects of
the systemic inﬂammatory response, it is clear from the plot of
NLR and CAR (Fig. 5e) that these ratios do not simply mirror one
another. In contrast, when cumulative scores such as NPS and
mGPS, based on normal reference ranges, were compared there
was better agreement in terms of systemic inﬂammatory response
status and prognostic value (Table 4). However, it should be noted
that although C-reactive protein and albumin are similar proteins
components of a differential WCC such as neutrophil count are
composed of a number of cell types.12 Irrespective the cumulative
score approach, based on normal reference ranges, improves our
understanding of aspects of the activation of the innate systemic
inﬂammatory response. The simplicity and consistency of this
approach has much to commend it.
The innate systemic inﬂammatory response in patients with
cancer, as well as incorporating responses from lymphoid/myeloid
tissue and the liver, incorporates responses from other organs and
tissues. In particular, the response from the sympathetic nervous
system is of interest since similar to that of NPS and mGPS, it is
intimately connected with immune responses.13 Having estab-
lished, in patients with cancer, the prognostic value of simple and
objective markers of activation of lymphoid/myeloid and liver
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tissue activation, it would be of considerable interest to examine
the prognostic value of objective markers of activation of the
sympathetic nervous system.
In the present study, there was a clear correlation between
higher composite ratios and cumulative scores and increased age,
BMI, advanced T stage and the presence of both venous and
peritoneal invasion. These clinicopathological characteristics are
also directly associated with a poorer prognosis adding further
weight to the prognostic ability of both composite ratios and
cumulative score in patients with colonic cancer.
Recently, Park et al.5 reported that the mGPS provides
complimentary prognostic information to current TNM-based
staging. When TNM staging and mGPS were combined, the 5-
year OS ranged from 92% (TNM 0, mGPS= 0) to 26% (stage III,
mGPS= 2) and the 10-year OS ranged from 92% (TNM 0, mGPS=
0) to 17% (TNM III, mGPS= 2) (p < 0.001). This further highlights
the prognostic ability of the mGPS which is complementary to the
gold standard of TNM staging with both being routinely available
worldwide.5
The present study has a number of possible limitations.
Although a relatively large prospective cohort, there were small
numbers of observations in some sub-group analysis. Further-
more, data relating to other factors that may have affected
markers of the systemic inﬂammatory response such drugs taken
prior to sampling were not available. Although the present study
used the 5th rather than the 7th edition of the TNM staging
system, this was recommended in the 2014 Colorectal Cancer Care
Guidelines of the Royal College of Pathologists and as such is the
basis for all current UK wide practice.14 Furthermore, migration
from the 5th to 7th edition would be expected to account for an
upstaging from node-negative to node-positive disease in <3% of
cases, with little subsequent effect on prognosis.14–16
A maximum of a 30-day interval between laboratory testing and
surgery may be considered to be too long. However, this timescale
has been widely reported in the literature and consistent with the
chronic nature of the standardised incidence ratio in patients with
cancer.3 Also, patients with inﬂammatory bowel disease-related
cancers were not included in the analysis. As such, the patient
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confounding factors of active systemic inﬂammatory disease and
acute changes in the inﬂammatory state have been minimised.
In summary, present study directly compares, for the ﬁrst time,
the prognostic value of composite ratios and cumulative scores of
the systemic inﬂammatory response. These ratios and scores,
whether composed of white cells from lymphoid/myeloid tissue or
from acute phase proteins from the liver, had prognostic value,
independent of TNM stage, in patients with colon cancer.
However, cumulative scores, based on normal reference ranges,
are simpler and more consistent for clinical use.
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